I know this is in rats but who is going to take the lead in researching this in humans? Survivors need tons of motivation since our doctors are leaving us disabled with no path to get to full recovery. It however helps to inhibit nogo-A for recovery.
Inhibition of Nogo: a key strategy to increase regeneration, plasticity and functional recovery of the lesioned central nervous system
The latest here:
Reduced expression of Nogo-A leads to motivational deficits in rats
Thomas Enkel1*, Stefan M. Berger1, Kai Schönig1, Björn Tews2 and Dusan Bartsch1- 1Department of Molecular Biology, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany
- 2Schaller Research Group, Division of Molecular Mechanisms of Tumor Invasion, University of Heidelberg and German Cancer Research Center, Heidelberg, Germany
Introduction
Nogo-A is an important neurite growth-regulatory protein in the developing and adult nervous system (Schwab, 2010).
While research originally focused on oligodendrocytic Nogo-A and its
role in injury and repair of fiber tracts in the CNS, the fact that
Nogo-A was found to be present also in neurons (Huber et al., 2002) has risen interest in its involvement in the generation of general behavior, as well. Indeed, in a wide-ranging analysis, Willi et al. (2009, 2010) could demonstrate behavioral alterations in Nogo-A knockout (Nogo-A−/−) mice.
Recently, Nogo-A deficiency could be established in
the rat species by using a transgenic, constitutively expressed
artificial microRNA leading to a 50% reduction of Nogo-A levels in
neurons (Tews et al., 2013). Similar to Nogo-A−/−
mice, these Nogo-A deficient rats exhibited a variety of behavioral
deficits, such as reduced pre-pulse inhibition of the acoustic startle
response, behavioral inflexibility, and impairments in short-term
memory. In addition, pronounced alterations in social behavior were
found. Conducting basic research or preclinical studies in rats offer
the advantage that, for example, they more readily learn difficult
cognitive behavioral tasks and exhibit more complex social behaviors
than mice (Poole and Fish, 1975; McNamara et al., 1996; Costantini and D’Amato, 2006; Cressant et al., 2007).
Further, the rat Nogo-A knockdown model uses the well-characterized
Sprague Dawley outbred strain and therefore offers increased
translational value compared to inbred mice, which is particularly
important when evaluating a possible role of neuronal growth regulation
in psychiatric disorders (Tews et al., 2013). This latter point is of interest, as the behavioral and structural phenotypes of Nogo-A−/− mice and Nogo-A deficient rats make them potential tools to investigate the pathology of schizophrenia (SCZ; Kristofikova et al., 2013; Willi and Schwab, 2013).
Schizophrenia is a common and debilitating psychiatric disorder and believed to result from neurodevelopmental disturbances (Keshavan et al., 2008; Tandon et al., 2008; Lewis and Sweet, 2009).
Interestingly, neuronal Nogo-A is highly expressed particularly during
early neuronal development and down regulated later during adulthood in
most regions, except the hippocampus, suggesting an important role in
neuronal network formation (Huber et al., 2002; Kempf and Schwab, 2013; Mironova and Giger, 2013).
In the current study, we aimed to investigate the consequences of
Nogo-A deficiency with respect to two important aspects of the negative
spectrum of SCZ symptoms, which have not yet been explored in rats nor
in mice: avolition, a decrease in the motivation to take action and pursue goals, and anhedonia, the reduced ability to experience positive affect through reward (Tandon et al., 2009). The negative symptoms of SCZ have been particularly linked to genetic liability and neurodevelopmental disturbances (Dominguez et al., 2010).
Further, it has been described before that interference with neuronal
development by lesioning the neonatal brain can affect reward
sensitivity (Le Pen et al., 2002) or motivated behavior (Schneider and Koch, 2005).
Motivational states in rats can be made accessible to
quantification by the use of operant progressive ratio schedules
introduced by Hodos and colleagues (Hodos, 1961; Hodos and Kalman, 1963).
In this test, subjects need to exhibit progressively increasing effort
(more lever pressing) to gain a stable amount of reward; the operant
demand at which reward-related responding ceases is termed the “break
point” and can serve as an index for reinforcer efficacy or a rat’s
motivational state (Barr and Phillips, 1998; Reilly, 1999; Mobini et al., 2000).
In the Nogo-A deficient rat, we employed the spontaneous progressive
ratio test (PR-Test) and additionally assessed operant responding under
extinction conditions, i.e., when rewards were completely omitted.
Reward sensitivity was investigated in a well-validated limited access
consumption task for sweet rewards (Enkel et al., 2010; Schneider et al., 2010).
Finally, to relate behavioral findings to underlying neurochemistry, we
analyzed dopamine and serotonin (5-HT) content in brain regions
associated with reward processing, namely nucleus accumbens (NAcc),
dorsal striatum (dSTR), and prefrontal cortex (PFC).
No comments:
Post a Comment